In last trading session, Acceleron Pharma Inc. (NASDAQ:XLRN) saw 1,630,139 shares changing hands with its beta currently measuring 0.75. Company’s recent per share price level of $101.93 trading at -$0.6 or -0.61% at ring of the bell on the day assigns it a market valuation of $5.49 Billion. That closing price of XLRN’s stock is at a discount of -8.4% from its 52-week high price of $110.49 and is indicating a premium of 63.11% from its 52-week low price of $37.6. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 616.16 Million shares which gives us an average trading volume of 458.75 Million if we extend that period to 3-months.
For Acceleron Pharma Inc. (XLRN), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2. Splitting up the data highlights that, out of 12 analysts covering the stock, 1 rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 10 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.66 in the current quarter.
Acceleron Pharma Inc. (NASDAQ:XLRN) trade information
In the face of being in the red today for losing -0.59%, in the last five days XLRN remained trading in the green while hitting it’s week-highest on Tuesday, Jun 23 when the stock touched $110.49 price level, adding 7.75% to its value on the day. Acceleron Pharma Inc.’s shares saw a change of 92.25% in year-to-date performance and have moved 2.58% in past 5-day. Acceleron Pharma Inc. (NASDAQ:XLRN) showed a performance of 3.39% in past 30-days. Number of shares sold short was 3.71 Million shares which calculate 0.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $124.17 to the stock, which implies a rise of 21.82% to its current value. Analysts have been projecting $88 as a low price target for the stock while placing it at a high target of $140. It follows that stock’s current price would jump +37.35% in reaching the projected high whereas dropping to the targeted low would mean a loss of -13.67% for stock’s current value.
Acceleron Pharma Inc. (XLRN) estimates and forecasts
Statistics highlight that Acceleron Pharma Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added +93.16% of value to its shares in past 6 months, showing an annual growth rate of 32.35% while that of industry is 9.5. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -94.1% in the current quarter and calculating 30.2% increase in the next quarter. This year revenue growth is estimated to rise 1.2% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $24.65 Million for the same. And 9 analysts are in estimates of company making revenue of $25.98 Million in the next quarter that will end in September 01, 2020. Company posted $26.14 Million and $4.21 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -5.7% while estimating it to be 517.4% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -7.9% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 8.1% while estimates for its earnings growth in next 5 years are of 0%
Acceleron Pharma Inc. (NASDAQ:XLRN)’s Major holders
Insiders are in possession of 13.5% of company’s total shares while institution are holding 90.09% percent of that, with stock having share float percentage of 104.16%. Investors also watch the number of corporate investors in a company very closely, which is 271 institutions for Acceleron Pharma Inc. that are currently holding shares of the company. FMR, LLC is the top institutional holder at XLRN for having 8Million shares of worth $718.97 Million. And as of March 30, 2020, it was holding 14.86% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 5.12 Million shares on March 30, 2020. The number of shares represents firm’s hold over 9.51% of outstanding shares, having a total worth of $460.07 Million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of February 28, 2020, the former fund manager was holding 1703258 shares of worth $146.36 Million or 3.16% of the total outstanding shares. The later fund manager was in possession of 1.32 Million shares on March 30, 2020, making its stake of worth around $119.02 Million in the company or a holder of 2.46% of company’s stock.